Integer (ITGR) - 2025 Q2 - Quarterly Results

Financial Highlights and Outlook This section presents Integer's strong Q2 2025 financial performance and its updated full-year 2025 outlook Second Quarter 2025 Highlights Integer reported strong Q2 2025 results with double-digit growth in sales, adjusted operating income, and adjusted EPS, driven by the continued execution of its strategy - Integer's President and CEO, Joseph Dziedzic, highlighted the strong quarter with 11% sales growth, 15% adjusted operating income growth, and 19% adjusted EPS growth[3] - Total debt increased by $212 million from the end of 2024 to $1.202 billion Net total debt increased by $250 million to $1.204 billion, resulting in a leverage ratio of 3.2 times adjusted EBITDA[5] Q2 2025 Financial Highlights vs. Q2 2024 | Metric | Q2 2025 | Change vs. Q2 2024 | | :--- | :--- | :--- | | Sales | $476 million | +11% | | GAAP Operating Income | $59 million | +9% | | Non-GAAP Adjusted Operating Income | $81 million | +15% | | GAAP Income from Continuing Operations | $37 million | +19% | | Non-GAAP Adjusted Net Income | $55 million | +23% | | GAAP Diluted EPS from Continuing Operations | $1.04 | +18% | | Non-GAAP Adjusted EPS | $1.55 | +19% | | Adjusted EBITDA | $99 million | +10% | 2025 Full Year Outlook The company raised its full-year 2025 profit outlook, now expecting adjusted operating income growth of 12-16% and adjusted EPS growth of 18-23% - Projected non-GAAP adjustments for 2025 include approximately $87 million pre-tax for adjusted operating income and $134 million pre-tax for adjusted net income These adjustments primarily consist of amortization, restructuring, acquisition costs, and debt conversion expenses[8][9] 2025 Full Year Outlook (in millions, except per share) | Metric | GAAP | Change from Prior Year | Adjusted (Non-GAAP) | Change from Prior Year | | :--- | :--- | :--- | :--- | :--- | | Sales | $1,850 to $1,876 | 8% to 9% | N/A | N/A | | Operating income | $232 to $244 | 11% to 17% | $319 to $331 | 12% to 16% | | EBITDA | N/A | N/A | $402 to $418 | 11% to 16% | | Income from continuing operations | $100 to $109 | (17)% to (10)% | $222 to $231 | 21% to 26% | | Diluted earnings per share | $2.79 to $3.05 | (20)% to (13)% | $6.25 to $6.51 | 18% to 23% | Financial Performance Analysis This section details Integer's product line sales performance and summarizes key financial results for Q2 and YTD 2025 Product Line Sales Performance In Q2 2025, Cardio & Vascular sales grew strongly by 24.0% (17.6% organic), while Other Markets sales declined due to a planned exit - Growth in the Cardio & Vascular segment was driven by new product introductions in electrophysiology, contributions from the Precision Coating and VSi Parylene acquisitions, and strong neurovascular demand[6] - The decline in the Other Markets segment was primarily due to the planned multi-year exit from the portable medical market, which was announced in 2022[6] Product Line Sales (Q2 & YTD 2025 vs 2024) | Product Line | Q2 2025 Sales ($M) | QTD Change | QTD Organic Change | YTD 2025 Sales ($M) | YTD Change | YTD Organic Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Cardio & Vascular | $286.9 | 24.0% | 17.6% | $545.7 | 20.4% | 14.3% | | Cardiac Rhythm Management & Neuromodulation | $172.0 | 2.3% | 2.3% | $332.3 | 2.3% | 2.3% | | Other Markets | $17.6 | (37.9)% | (1.8)% | $35.8 | (37.6)% | (12.8)% | | Total Sales | $476.5 | 11.4% | 10.8% | $913.9 | 9.4% | 8.6% | Summary Financial Results The company's summary financials show increased Q2 2025 adjusted net income and EPS, but a sharp YTD GAAP decline due to a debt conversion expense - The significant year-to-date decrease in GAAP income from continuing operations was heavily impacted by a $46.7 million debt conversion inducement expense related to the partial exchange of the 2028 Convertible Notes[41][50] Summary Financial Results (in thousands, except per share data) | Metric | Q2 2025 | Q2 2024 | QTD Change | YTD 2025 | YTD 2024 | YTD Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Operating income | $59,338 | $54,494 | 8.9% | $108,890 | $93,195 | 16.8% | | Income from continuing operations | $37,009 | $31,207 | 18.6% | $14,544 | $51,798 | (71.9)% | | Diluted EPS from continuing operations | $1.04 | $0.88 | 18.2% | $0.41 | $1.47 | (72.1)% | | Adjusted operating income | $81,266 | $70,825 | 14.7% | $152,189 | $133,020 | 14.4% | | Adjusted net income | $54,818 | $44,683 | 22.7% | $100,756 | $83,351 | 20.9% | | Adjusted EPS | $1.55 | $1.30 | 19.2% | $2.85 | $2.44 | 16.8% | Consolidated Financial Statements This section provides an overview of Integer's condensed consolidated balance sheets, statements of operations, and cash flows Condensed Consolidated Balance Sheets As of June 27, 2025, total assets increased to $3.37 billion, driven by goodwill and intangibles, while total liabilities grew to $1.67 billion due to rising long-term debt Balance Sheet Summary (in thousands) | Account | June 27, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Total Current Assets | $737,430 | $671,119 | | Goodwill | $1,100,371 | $1,017,729 | | Other intangible assets, net | $854,545 | $778,286 | | Total Assets | $3,370,935 | $3,077,971 | | Total Current Liabilities | $216,030 | $227,173 | | Long-term debt | $1,202,495 | $980,153 | | Total Liabilities | $1,667,398 | $1,458,756 | | Total Stockholders' Equity | $1,703,537 | $1,619,215 | Condensed Consolidated Statements of Operations For Q2 2025, sales and operating income increased, but a significant 'Other (income) loss' for the six-month period reduced income from continuing operations Statement of Operations Summary (in thousands) | Account | Three Months Ended June 27, 2025 | Six Months Ended June 27, 2025 | | :--- | :--- | :--- | | Sales | $476,494 | $913,886 | | Gross Profit | $129,152 | $249,470 | | Operating Income | $59,338 | $108,890 | | Other (income) loss, net | $3,980 | $51,907 | | Income from continuing operations | $37,009 | $14,544 | | Net Income | $37,009 | $14,522 | | Diluted EPS | $1.04 | $0.41 | Condensed Consolidated Statements of Cash Flows For the first six months of 2025, operating activities provided $75.1 million, while investing activities used $215.0 million, primarily for acquisitions Cash Flow Summary - Six Months Ended (in thousands) | Activity | June 27, 2025 | June 28, 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $75,138 | $70,474 | | Net cash used in investing activities | ($214,994) | ($198,796) | | Net cash provided by financing activities | $115,989 | $138,768 | | Net (decrease) in cash and cash equivalents | ($23,408) | $10,463 | Reconciliation of GAAP to Non-GAAP Financial Measures This section provides detailed reconciliations of GAAP financial measures to their corresponding non-GAAP adjusted counterparts Table A: Adjusted Net Income and Diluted EPS This table reconciles GAAP income from continuing operations to non-GAAP adjusted net income, highlighting the impact of a significant debt conversion inducement expense - For the six months ended June 27, 2025, a debt conversion inducement expense of $46.7 million was a major reconciling item between GAAP and non-GAAP net income[41][50] Q2 2025 Net Income Reconciliation (in thousands) | Description | Pre-Tax | Net of Tax | | :--- | :--- | :--- | | Income from continuing operations (GAAP) | $45,596 | $37,009 | | Amortization of intangible assets | $16,120 | $12,978 | | Restructuring and restructuring-related charges | $2,575 | $2,049 | | Acquisition and integration costs | $2,007 | $1,596 | | Adjusted net income (non-GAAP) | $67,662 | $54,818 | Table B: Adjusted Operating Income This table reconciles GAAP operating income to non-GAAP adjusted operating income, primarily by adding back amortization of intangible assets Q2 2025 Operating Income Reconciliation (in thousands) | Description | Amount | | :--- | :--- | | Operating income (GAAP) | $59,338 | | Amortization of intangible assets | $16,120 | | Restructuring and restructuring-related charges | $2,575 | | Acquisition and integration costs | $2,007 | | Adjusted operating income (non-GAAP) | $81,266 | Table C: EBITDA This table reconciles GAAP income from continuing operations to non-GAAP EBITDA and adjusted EBITDA, including adjustments for interest, taxes, depreciation, and amortization Q2 2025 EBITDA Reconciliation (in thousands) | Description | Amount | | :--- | :--- | | Income from continuing operations (GAAP) | $37,009 | | Interest expense | $9,754 | | Provision for income taxes | $8,587 | | Depreciation | $15,040 | | Amortization of intangible assets and financing leases | $17,246 | | EBITDA (non-GAAP) | $87,636 | | Stock-based compensation | $5,499 | | Other adjustments (Restructuring, Acquisition, etc.) | $5,808 | | Adjusted EBITDA (non-GAAP) | $98,951 | Table D: Organic Sales Change This table reconciles GAAP reported sales growth to non-GAAP organic sales growth by adjusting for foreign currency impacts and strategic exits/acquisitions Q2 2025 Sales Growth Reconciliation (%) | Product Line | GAAP Reported Growth | Impact of Foreign Currency | Impact of Exits and Acquisitions | Non-GAAP Organic Change | | :--- | :--- | :--- | :--- | :--- | | Cardio & Vascular | 24.0% | 0.3% | 6.1% | 17.6% | | Other Markets | (37.9)% | —% | (36.1)% | (1.8)% | | Total Sales | 11.4% | 0.2% | 0.4% | 10.8% | Table E: Net Total Debt This table reconciles total debt to non-GAAP net total debt by subtracting cash and cash equivalents from the total principal amount of debt outstanding Net Total Debt Reconciliation (in thousands) | Description | June 27, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Total debt (GAAP) | $1,202,495 | $990,153 | | Total principal amount of debt outstanding | $1,227,301 | $1,000,994 | | Less: Cash and cash equivalents | $23,135 | $46,543 | | Net Total Debt (Non-GAAP) | $1,204,166 | $954,451 | Supplementary Information This section provides important context regarding the company's use of non-GAAP financial measures and outlines key forward-looking statements and risk factors Notes Regarding Non-GAAP Financial Information The company uses non-GAAP measures to provide supplemental information on business trends, excluding specific items to enhance comparability of financial results - Adjusted net income and adjusted EPS exclude items such as amortization of intangibles, certain legal expenses, restructuring costs, acquisition costs, and gains/losses on equity investments[23] - Organic sales change is a non-GAAP measure that adjusts reported sales growth to remove the impacts of foreign currency fluctuations, acquisitions, and the strategic exit of the Portable Medical market[27] - The company believes these non-GAAP measures provide important supplemental information to management and investors for understanding financial and business trends[28] Forward-Looking Statements and Risk Factors The report contains forward-looking statements subject to various risks, including operational, strategic, financial, and legal/compliance factors - The press release contains forward-looking statements concerning the 2025 outlook and future performance, which are predictions and may differ materially from actual results[29] - Key operational risks include dependence on a limited number of customers, pricing pressures, and reliance on third-party suppliers[30] - Key financial and strategic risks include intense competition, ability to integrate acquisitions, significant outstanding debt, and economic uncertainties affecting access to capital[34]